| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 26 | 160 | - | 48 |
| Research and development (includes 13, (2), 19 and (32) from a related party) | 141 | 139 | - | 123 |
| General and administrative (includes 3, , 5, and from a related party) | 27 | 29 | - | 30 |
| Impairment of long-lived assets | 0 | 0 | - | - |
| Total operating expenses | 168 | 168 | - | 153 |
| Loss from operations | -142 | -8 | -122 | -105 |
| Interest and other income, net | 10 | 10 | 11 | 14 |
| Interest expense | 3 | 2 | 1 | 1 |
| Total non-operating income, net | 7 | 8 | 10 | 13 |
| Loss before income taxes | -135 | 0 | -112 | -92 |
| Income tax expense | 0 | 0 | - | - |
| Net loss | -135 | 0 | -112 | -92 |
| Basic (in dollars per share) | -1.27 | 0 | -1.14 | -1 |
| Basic (in shares) | 106,500,000 | 106,100,000 | 98,400,000 | 91,400,000 |
| Diluted (in dollars per share) | -1.27 | 0 | -1.14 | -1 |
| Diluted (in shares) | 106,500,000 | 106,500,000 | 98,400,000 | 91,400,000 |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)